Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Blood (2023) 142 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2023-180010

Published: 2023

Journal Articles

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Eytan M. Stein, MD, Courtney D. DiNardo, MDMSc, Alice S. Mims, MD MSCR, Michael R. Savona, MD, Keith Pratz, MD, Anthony S. Stein, MD, Amir T. Fathi, MD MD BS, Richard M. Stone, MD, Daniel A. Pollyea, MD, Olatoyosi Odenike, MD, Bob Lowenberg, MD PhD, Hartmut Döhner, MD, Gary J. Schiller, Ira V. Gupta, MD, Salah Nabhan, Vickie Zhang, PhD, Caroline Almon, MS, Michael Cooper, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 726.

https://doi.org/10.1182/blood.V130.Suppl_1.726.726

Published: 2017

Journal Articles

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Tadeusz Robak, MD Professor, Krzysztof Warzocha, MD PhD, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, MD PhD, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, PhD, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, MD, Sebastian Grosicki, MD PhD

Blood (2015) 126 (23): 5288.

https://doi.org/10.1182/blood.V126.23.5288.5288

Published: 2015

Journal Articles

NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)

Eugen Tausch, MD, Philipp Beck, Richard F. Schlenk, MD, Sabrina Kless, Christina Galler, Peter Hillmen, MB ChB, PhD, Fritz Offner, MD, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Susanne Danhauser-Riedl, MD, Astrid McKeown, PhD, Paul D P´B Winter, PhD, Ira V Gupta, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 527.

https://doi.org/10.1182/blood.V122.21.527.527

Published: 2013

Journal Articles

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Peter Hillmen, MB ChB, PhD, Tadeusz Robak, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Eva Kimby, MD, Anna Schuh, MD, Thomas Boyd, MD, Marco Montillo, MD, Astrid McKeown, PhD, Jodi L Carey, RN, BSN, Ira V Gupta, MD, Chai-Ni Chang, MS, Steen Lisby, MD, DMSc, Fritz Offner, MD

Blood (2013) 122 (21): 528.

https://doi.org/10.1182/blood.V122.21.528.528

Published: 2013

Journal Articles

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Myron S. Czuczman, MD, Georg Hess, Ole Gadeberg, Lars Moeller Pedersen, Per Hansen, David Belada, M.D., Ph.D., Stephanie A. Gregory, MD, Brad Pohlman, MD, Jiri Mayer, M.D., PhD., Prof., Robert Pytlik, Lorenz Trumper, Andreas Viardot, MD, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Paul Winter, Nancy Goldstein, Roxanne C. Jewell, PhD, Steen Lisby, MD, DMSc

Blood (2012) 120 (21): 1632.

https://doi.org/10.1182/blood.V120.21.1632.1632

Published: 2012

Journal Articles

Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy

William G. Wierda, MD, PhD, Roxanne C. Jewell, PhD, Thomas J. Kipps, M.D., Ph.D, Jan Dürig, MD, Laimonas Griskevicius, Stephan Stilgenbauer, MD, Lukas Smolej, M.D., Ph.D., Georg Hess, Francisco J. Hernandez-Ilizaliturri, MD, Swaminathan Padmanabhan, MBBS, MD, Lei Fang, Michele M. Gorczyca, MS, Geoffrey W. Chan, MD, Ira V. Gupta, MD, Steen Lisby

Blood (2011) 118 (21): 1793.

https://doi.org/10.1182/blood.V118.21.1793.1793

Published: 2011

Journal Articles

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

William G. Wierda, Swaminathan Padmanabhan, Geoffrey W. Chan, Ira V. Gupta, Steen Lisby, Anders Österborg, for the Hx-CD20-406 Study Investigators

Blood (2011) 118 (19): 5126–5129.

https://doi.org/10.1182/blood-2011-04-348656

Published: 2011

Journal Articles

Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

Bertrand Coiffier, MD, PhD, André Bosly, MD, Ka Lung Wu, MD, PhD, Gregor Verhoef, MD, PhD, Van Eygen Koen, MD, Giovanni Martinelli, MD, Gabriela Barca, MD, PhD, Andrew Davies, MRCP, PhD, Eve Gallop-Evans, PhD, Swaminathan Padmanabhan, MBBS, MS, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Randy L. Davis, DrPH, Nedjad Losic, MSC, Steen Lisby, MD, DMSC, John A. Radford, MD

Blood (2010) 116 (21): 3955.

https://doi.org/10.1182/blood.V116.21.3955.3955

Published: 2010

Journal Articles

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Blood (2010) 116 (21): 921.

https://doi.org/10.1182/blood.V116.21.921.921

Published: 2010

NARROW

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only